Thus, the evaluation of future pharmacological studies or experimental gene therapeutic approaches for the treatment of dystrophinopathy should take into account that the deficiency in dystrophin does not affect all skeletal muscle subtypes in a similar manner. This evidence concerns the gene DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin.